Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe clinical-trial record for a completed study of brentuximab vedotin in Hodgkin lymphoma and CD30-expressing PTCL is now available, including participant criteria, treatment and outcome details, results, and study documents.SummaryDifference93%

- Check20 days agoChange DetectedThe site footer's revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe ClinicalTrials.gov site footer now identifies the release as v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study details. This blocks access to core study information and related content on the page.SummaryDifference20%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.